REG - RTW Biotech Opp. - Update on Rocket Pharmaceuticals

RTW Biotech OpportunitiesAnnouncement

19/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250519:nRSS0862Ja&default-theme=true

RNS Number : 0862J  RTW Biotech Opportunities Ltd  19 May 2025

LEI: 549300Q7EXQQH6KF7Z84

19 May 2025

RTW Biotech Opportunities Ltd

Update on Rocket Pharmaceuticals

 

RTW Biotech Opportunities Ltd (the "Company"), the London Stock
Exchange-listed investment company focused on identifying transformative
assets with high growth potential across the life sciences sector, is pleased
to note the 15 May announcement by one of its public portfolio companies,
Rocket Pharmaceuticals ("Rocket", NASDAQ:RCKT), of preliminary data from its
Phase 1 clinical trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy
(PKP2-ACM) at the  annual meeting of the American Society of Gene and Cell
Therapy. PKP2-ACM is a rare disease that affects ~50,000 people in the US and
EU alone.

 

Rocket is a late-stage biotech company advancing a pipeline of investigational
genetic therapies designed to correct the root cause of complex and rare
disorders. RP-A601 is being investigated as a one-time, potentially curative
gene therapy treatment that may improve survival and quality of life for
affected patients. RP-A601 showed a well-tolerated safety profile with no
dose-limiting toxicities, increased PKP2 protein expression, and preliminary
indications of improvement or stabilisation in arrhythmia burden, heart
function, and quality of life. It is the second drug in Rocket's pipeline to
directly target a large genetic cardiac disease.

 

Rocket is an original company creation of RTW Investments and was founded in
2015, going public through a reverse merger in 2018. As at 30 April, Rocket
represented 3.2% of the Company's NAV. Rocket's share price closed up 11.1% on
15 May, the day of announcement.

 

Rod Wong, CIO of RTW Investments, said, "We are excited to see this
encouraging preliminary data from Rocket's RP-A601's Phase 1 clinical trial,
which we flagged as a key catalyst in the Company's annual results on 31 March
2025, demonstrating clear progress on Rocket's aim to deliver potentially
curative treatments to patients with rare and devastating heart conditions. We
look forward to updating the Company's shareholders on this and other exciting
future developments at Rocket, with the next proximate catalyst being results
of patient dosing for treatment of Danon disease, expected this quarter."

 

The full text of the announcement can be read at
 https://www.rocketpharma.com
(https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-presents-preliminary-data-phase-1)
.

 

Enquiries:

 RTW Investments, LP - Investment Manager               +44 (0)20 7959 6361

 Woody Stileman (Business Development)                  biotechopportunities@rtwfunds.com

 Oliver Kenyon (Business & Corporate Development)

 Krisha McCune (Investor Relations)

 Cadarn Capital - PR & IR Partner

 Lucy Clark (PR)                                        +44 (0)7984 184 461 / lucy@cadarncapital.com

 David Harris (Distribution)                            +44 (0)7368 883 211 / david@cadarncapital.com

 Deutsche Numis - Joint Corporate Broker                +44 (0)20 7260 1000

 Freddie Barnfield

 Nathan Brown

 Euan Brown

 BofA Securities - Joint Corporate Broker               +44 (0)20 7628 1000

 Edward Peel

 Alex Penney

 Altum (Guernsey) Limited                               +44 (0)1481 703 100

 Joanna Duquemin Nicolle

 Sadie Morrison

 

 

 

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on
identifying transformative assets with high growth potential across the
biopharmaceutical and medical technology sectors. Driven by a long-term
approach to support innovative businesses, RTW Biotech Opportunities Ltd
invests in companies developing next-generation therapies and technologies
that can significantly improve patients' lives. RTW Biotech Opportunities Ltd
is managed by RTW Investments, LP, a leading healthcare-focused
entrepreneurial investment firm with deep scientific expertise and a strong
track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd
(https://www.rtwfunds.com/rtw-biotech-opportunities-ltd/)  for more
information.

 

***********

The information in this announcement may include forward-looking statements,
which are based on the current expectations and projections about future
events, and in certain cases can be identified by the use of terms such as
"may", "will", "should", "expect", "anticipate", "project", "estimate",
"intend", "continue", "target", "believe" (or the negatives thereon) or other
variations thereon or comparable terminology. These forward-looking
statements, as well as those included in any related materials, are subject to
risks, uncertainties and assumptions about the Company and/or its underlying
investments, including, among other things, the development of the applicable
entity's business, trends in its operating industry, expected use of financing
proceeds and future capital expenditures and acquisitions. In light of these
risks, uncertainties and assumptions, the events in the forward-looking
statements may not occur.

The information contained in this announcement is given at the date of its
publication (unless otherwise marked). No reliance may be placed for any
purpose whatsoever on the information or opinions contained in this
announcement or on its completeness, accuracy or fairness.

***********

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGPUQAAUPAGAQ